Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.91 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TET3 | O43151 | 1/20 | 0.54 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.54 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.54 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.54 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8105149 | 0.98 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL11665752 | 0.98 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL65167 | 0.95 | AKR1C1 (1.00) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL66387 | 0.93 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| Hydrochloric Acid SCHEMBL8315894 | 0.93 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL1042420 | 0.93 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL1041902 | 0.93 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL19249602 | 0.93 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL3811046 | 0.91 | AKR1C1 (0.92) | AKR1C1HDAC4KMT2AMEN1TET3 | |
| SCHEMBL6391 | 0.91 | AKR1C1 (0.83) | AKR1C1HDAC4KMT2AMEN1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4377295-B1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-0118283-A1 | Phenyl-cyclobutane carboxylates as arthropodicides | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1984-09-12 | — | — | EP | disclosed |
| EP-0037375-B1 | INSECTICIDAL-VAPOURS EMITTING DEVICE | Airwick AG (CH) | 1984-05-23 | — | — | EP | disclosed |
| US-4439415-A | PYRETHRINOID AND ABSORPTIVE SUBSTRATE | AIRWICK INDUSTRIES, INC. (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0037375-A1 | Insecticidal-vapours emitting device | Airwick AG (CH) | 1981-10-07 | — | — | EP | disclosed |
| US-4130656-A | INSECTICIDE, MITICIDE | CIBA-GEIGY CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
| US-4130656-A | INSECTICIDE, MITICIDE | CIBA-GEIGY CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
| US-4117119-A | 15-CYCLOBUTYL-PROSTAGLANDINS | ONO PHARMACEUTICAL COMPANY (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4093630-A | ANTIHISTAMINES | HOKURIKU PHARMACEUTICAL CO., LTD. (JA) | 1978-06-06 | — | — | US | disclosed |
| US-4045468-A | GASTRIC ULCERS | ONO PHARMACEUTICAL COMPANY (JA) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | AKR1C1 1612/4885HDAC4 2520/4885KMT2A 2424/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | AKR1C1 4325/4885HDAC4 3206/4885KMT2A 3318/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | AKR1C1 4305/4885HDAC4 3176/4885KMT2A 3301/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | AKR1C1 4325/4885HDAC4 3206/4885KMT2A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.